Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model

Article activity feed

1. Version published to 10.1128/mbio.00974-21

   Aug 31, 2021
2. 

   ScreenIT

   Apr 7, 2021

   SciScore for 10.1101/2021.04.02.438292: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	Animals were randomly assigned to be euthanized at 2, 4, 7, 14, or 28-days post infection (dpi).
   Blinding	The investigators were blinded to the group assignments.
   Power Analysis	not detected.
   Sex as a biological variable	Animal experiments: Male and female golden Syrian hamsters (7-8 weeks of age) were purchased from Envigo (Haslett, MI).
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Antibody ELISAs: Hamster antibody ELISA protocol was modified from human COVID-19 antibody ELISA protocol described previously (14).	COVID-19 suggested: None
   After washing plates 3 times, HRP-conjugated secondary IgG (1:10000, …

   SciScore for 10.1101/2021.04.02.438292: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	Animals were randomly assigned to be euthanized at 2, 4, 7, 14, or 28-days post infection (dpi).
   Blinding	The investigators were blinded to the group assignments.
   Power Analysis	not detected.
   Sex as a biological variable	Animal experiments: Male and female golden Syrian hamsters (7-8 weeks of age) were purchased from Envigo (Haslett, MI).
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Antibody ELISAs: Hamster antibody ELISA protocol was modified from human COVID-19 antibody ELISA protocol described previously (14).	COVID-19 suggested: None
   After washing plates 3 times, HRP-conjugated secondary IgG (1:10000, Abcam, MA, USA), IgA (1:250, Brookwood Biomedical, AL, USA) or IgM (1:250, Brookwood Biomedical, AL, USA) antibodies were added.	HRP-conjugated secondary IgG suggested: (Creative Diagnostics Cat# LAB-22, RRID:AB_2489589) IgA suggested: None IgM suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   To obtain whole inactivated SARS-CoV-2, VeroTMPRSS2 cells were infected at a MOI of 0.01 and the infected cell culture supernatant was collected at 72 hours post infection.	VeroTMPRSS2 suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)
   Briefly, tissue homogenates were 10-fold serially diluted in infection media (CM with 2.5% instead of 10% FBS), transferred in sextuplicate into the 96-well plates confluent with Vero-E6-TMPRSS2 cells, incubated at 370C for 4 days, and stained with naphthol blue-black solution for visualization.	Vero-E6-TMPRSS2 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   Software and Algorithms
   Sentences	Resources
   Statistical Analyses: Statistical analyses were done in GraphPad Prism 9.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
   

   Identifier	Status	Title
   NCT04359329	Recruiting	Estrogen Patch for COVID-19 Symptoms
   NCT04539626	Recruiting	Estrogen Therapy in Non-severe COVID-19 Patients

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.04.02.438292 on bioRxiv

   Apr 4, 2021